• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Dictionary: Timely review of regulatory cases that come from the field is important as it allows FDA to take appropriate regulatory action such as issuance of a warning letter to the regulated industry. This can lead to a timely correction of problems in the industry resulting in a safer food supply.

Information is current as of March 31, 2014.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercentage
Oct 2010TBD77
Nov 2010TBD59
Dec 2010TBD79
Jan 2011TBD63
Feb 2011TBD55
Mar 2011TBD80
Apr 2011TBD45
May 2011TBD45
Jun 2011TBD51
Jul 2011TBD84
Aug 2011TBD96
Sep 2011TBD71

FY 2011 Overall: 63%

Total number of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A34
Nov 2010N/A32
Dec 2010N/A48
Jan 2011N/A37
Feb 2011N/A23
Mar 2011N/A39
Apr 2011N/A27
May 2011N/A35
Jun 2011N/A43
Jul 2011N/A21
Aug 2011N/A26
Sep 2011N/A27

FY 2011 Total: 392

Total number of regulatory cases referred to OFS in the month that are due within the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A44
Nov 2010N/A54
Dec 2010N/A61
Jan 2011N/A59
Feb 2011N/A42
Mar 2011N/A49
Apr 2011N/A60
May 2011N/A77
Jun 2011N/A84
Jul 2011N/A25
Aug 2011N/A27
Sep 2011N/A38

FY 2011 Total: 620

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.